HTFL

SEC source: 0001464521-26-000099 · form4.xml · derivative · entry 5

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,123 shares

Expires 2030-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These stock options are fully exercisable.

SEC source: 0001464521-26-000099 · form4.xml · derivative · entry 4

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,123 shares

Expires 2032-03-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These stock options are fully exercisable.

SEC source: 0001464521-26-000099 · form4.xml · nonDerivative · entry 3

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001464521-26-000099 · form4.xml · nonDerivative · entry 2

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001464521-26-000099 · form4.xml · nonDerivative · entry 1

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001464521-26-000097 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 457,935

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001464521-26-000085 · form4.xml · derivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000095 · form4.xml · derivative · entry 1

WELDON WILLIAM C · CIK 0001189019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000093 · form4.xml · derivative · entry 1

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000091 · form4.xml · derivative · entry 1

Cullivan Julie A · CIK 0001713207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000089 · form4.xml · derivative · entry 1

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow, Inc.'s annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000087 · form4.xml · derivative · entry 1

Riley Wayne Joseph · CIK 0001432895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 16,075 shares

Expires 2036-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

SEC source: 0001464521-26-000078 · form4.xml · derivative · entry 6

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,633

Underlying: Common Stock · 10,000 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025.

F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000078 · form4.xml · nonDerivative · entry 1

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025.

SEC source: 0001464521-26-000075 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 496,835

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001464521-26-000073 · form4.xml · derivative · entry 7

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,410

Underlying: Common Stock · 9,219 shares

Expires 2035-08-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025.

F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until August 7, 2029, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000073 · form4.xml · nonDerivative · entry 2

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,731

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025.

SEC source: 0001464521-26-000073 · form4.xml · nonDerivative · entry 1

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025.

SEC source: 0001464521-26-000067 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 519,397

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001464521-26-000059 · form4.xml · nonDerivative · entry 2

Verghese Vikram · CIK 0002079946 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,854

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000063 · form4.xml · nonDerivative · entry 2

Jones Marie L. · CIK 0001968991 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,083

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000061 · form4.xml · nonDerivative · entry 2

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,731

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000057 · form4.xml · nonDerivative · entry 2

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 541,959

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000059 · form4.xml · nonDerivative · entry 1

Verghese Vikram · CIK 0002079946 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,327

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000063 · form4.xml · nonDerivative · entry 1

Jones Marie L. · CIK 0001968991 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,165

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000061 · form4.xml · nonDerivative · entry 1

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,368

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001464521-26-000057 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 543,863

F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.

SEC source: 0001193125-26-198593 · ownership.xml · nonDerivative · entry 4

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,448,158

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.19, inclusive.

F5 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001193125-26-198593 · ownership.xml · nonDerivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,504,382

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.995, inclusive.

F5 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001193125-26-198593 · ownership.xml · nonDerivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 9,396,915

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.69, inclusive.

F5 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001193125-26-198593 · ownership.xml · nonDerivative · entry 1

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences III General Partner, LLC · CIK 0001952106 · 10% owner

Bain Capital Life Sciences Fund III, L.P. · CIK 0001875273 · 10% owner

BCLS Fund III Investments GP, LLC · CIK 0001952080 · 10% owner

BCLS Fund III Investments, LP · CIK 0001952107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,194,048

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.46, inclusive. The reporting person undertakes to provide to Heartflow, Inc., any security holder of Heartflow, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) of this Form 4.

F5 · ownership.nature: Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001464521-26-000055 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 549,163

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001464521-26-000052 · form4.xml · derivative · entry 13

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,633

Underlying: Common Stock · 40,766 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000052 · form4.xml · derivative · entry 12

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,399

Underlying: Common Stock · 19,111 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000052 · form4.xml · derivative · entry 11

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,298

Underlying: Common Stock · 291 shares

Expires 2031-04-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F5 · derivative.exercise_date: These stock options are fully exercisable.

SEC source: 0001464521-26-000052 · form4.xml · derivative · entry 10

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,849 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F5 · derivative.exercise_date: These stock options are fully exercisable.

SEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 5

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,002

F3 · kind: Includes the sale of 16,918 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F4 · price: This transaction was executed in multiple trades at price ranging from $24.03 to $25.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 4

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,535

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 3

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 2

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 1

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000050 · form4.xml · nonDerivative · entry 1

Lightcap Jeffrey C · CIK 0001519465 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 246,261

F1 · shares: On March 24, 2026, HCPCIV 1, LLC ("HCPCIV") effected a pro rata in-kind distribution of Heartflow, Inc. common stock to its members in accordance with its operating agreement, including 206,261 shares allocable to Mr. Lightcap based on his indirect interest in HCPCIV immediately prior to the distribution. Following the distribution, HCPCIV is being dissolved. After giving effect to the distribution, Mr. Lightcap's beneficial ownership is held directly (and no longer indirectly through HCPCIV) to the extent of the shares received.

SEC source: 0001519462-26-000002 · primary_doc.xml · nonDerivative · entry 1

HealthCor Partners Management LP · CIK 0001519462 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By HCPCIV I, LLC

Disclosed balance after: 0

F1 · kind: EACH SHARE OF COMMON STOCK WAS DISTRIBUTED TO FUND INVESTORS.

F1 · price: EACH SHARE OF COMMON STOCK WAS DISTRIBUTED TO FUND INVESTORS.

SEC source: 0001464521-26-000048 · form4.xml · derivative · entry 9

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,510

Underlying: Common Stock · 47,615 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F5 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000048 · form4.xml · derivative · entry 8

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,125

Underlying: Common Stock · 19,402 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F5 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

SEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 3

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,518

F3 · kind: Includes the sale of 16,918 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

F4 · price: This transaction was executed in multiple trades at price ranging from $25.00 to $28.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 2

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 1

Rogers Campbell · CIK 0001585724 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

SEC source: 0001464521-26-000046 · form4.xml · nonDerivative · entry 1

Farquhar John C.M. · CIK 0001900415 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 571,725

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.

SEC source: 0001464521-26-000028 · form4.xml · derivative · entry 2

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,412

Underlying: Common Stock · 8,667 shares

Expires 2033-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.